Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.

NCT06417801 · clinicaltrials.gov ↗
RECRUITING
Status
70
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AstraZeneca